SkylineDX

SkylineDx B.V. is a biotech company based in Rotterdam, the Netherlands, that specializes in the development, marketing, and commercialization of diagnostic tests utilizing gene signatures for personalized medicine in oncology. The company focuses on molecular diagnostic tests for blood cancers, including AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and MMprofiler, a microarray-based service for Multiple Myeloma that determines clinically relevant subtypes. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance the development and commercialization of companion diagnostics and other tests aimed at aiding healthcare professionals in making individualized therapy decisions. Founded in 2005, SkylineDx has established a strategic collaboration with the Mayo Clinic to enhance its diagnostic offerings.

http://skylinedx.com

https://crunchbase.com/organization/skylinedx

https://facebook.com/skylinedx92

https://linkedin.com/company/skylinedx-bv

https://pitchbook.com/profiles/company/54790-30

https://twitter.com/skylinedx

https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=37615446

Dharminder Chahal

CEO

1 past transactions

DCPrime

Corporate Round in 2014

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.